# Wojciech Szwankowski

> Wojciech Szwankowski is a Series A investor at Montis Capital Group backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Montis Capital Group](https://shizune.co/investors/profile/montis-capital-group)
- Location: Warsaw, Poland
- Total investments: 3
- Last investment: Aug 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://pl.linkedin.com/in/wojtek-szwankowski-2598551/de

Wojciech Szwankowski is a Series A investor at Montis Capital Group in Warsaw focused on Biotechnology and Medical. Wojciech Szwankowski is the Managing Partner at Montis Capital Group. Attended NEOMA Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Big Data | 1 | 33% |
| Analytics | 1 | 33% |
| Marketing | 1 | 33% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Post-IPO Equity | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Poland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Proteon Pharmaceuticals | PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improveperformance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy. | $24.6M | Venture - Series Unknown | Aug 10, 2021 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $24.6M | Post-IPO Equity | Aug 10, 2021 |  |
| Plum Research | Plum Research is dedicated to providing clients with the most reliable data available in order for them to best serve their audience, maximize marketing dollars and increase ROI. | $2.7M | Series A | Jul 28, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Aqua Spark](https://shizune.co/investors/profile/aqua-sparks) — VC Fund, 3 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 3 deals together
- [Nutreco](https://shizune.co/investors/profile/nutreco) — VC Fund, 2 deals together
- [PFR Life Science](https://shizune.co/investors/profile/pfr-life-science) — VC Fund, 2 deals together
- [Tar Heel Capital Pathfinder](https://shizune.co/investors/profile/tar-heel-capital-pathfinder) — VC Fund, 1 deal together

## About Montis Capital Group

VC Fund · Warsaw, Poland

Montis Capital seeks to work with great teams, scalable business models, innovative and already market validated products on providing for expansion and growth capital within the following two sectors:Industry 4.0:We aim to be at the heart of a Fourth Industrial Revolution by investing into a confluence of robotics, artificial intelligence,internet of things, big data or deep tech.Life Science:We look for projects in fields of biotechnology, pharmaceuticals, biomedical technologies, life systems technologies, nutraceuticals, cosmeceuticals, food processing, environmental and biomedical devices.

5 contacts available at Montis Capital Group.

| Name | Title | Profile |
| --- | --- | --- |
| Wojciech Szwankowski | Managing Partner | https://shizune.co/investors/profile/wojciech-szwankowski |
| Katarzyna Laszczynowska | Head of Legal & Compliance | https://shizune.co/investors/profile/katarzyna-laszczynowska |
| Lukasz Dziekonski | Managing Partner | https://shizune.co/investors/profile/lukasz-dziekonski |
| Michal Gaweda | Investment Manager | https://shizune.co/investors/profile/michal-gaweda |
| Tomasz Poninski | Managing Partner | https://shizune.co/investors/profile/tomasz-poninski |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Wojciech Szwankowski invest in?

Wojciech Szwankowski invests primarily in Biotechnology, Medical and Big Data startups, most often at Series A and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wojciech Szwankowski last invest?

The most recent investment recorded for Wojciech Szwankowski closed in Aug 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co